Orthotopic, Bioluminescent Ovarian Cancer Xenograft Models Developed

Establishment and Characterization of Human Ovarian Cancer Xenograft Models using Bioluminescence Imaging

Nektaria Papadopoulou, Louise Wainwright, Vicky Lacey, Jane Wrigley, Jamie Wood, Sumanjeet Malhi, Louise Woolley, Jason King, Simon Jiang, and Rajendra Kumari

Due to late diagnoses and common treatment failure, ovarian cancer has a high lethality, and is the major cause of cancer-related death in women. Advanced preclinical models are required to improve the understanding of ovarian cancer biology, and to make ovarian cancer drug development more efficient.

It is widely accepted that orthotopic cancer models are more clinically relevant than their subcutaneous counterparts. This is due to orthotopic tumors establishing at organ specific sites, forming more patient comparable tumor vasculature/microenvironment, and facilitating spontaneous metastatic spread.

Combining orthotopic models with bioluminescent imaging (BLI) allows non-invasive longitudinal monitoring of orthotopic tumor burden, assists in optimal randomization, and also provides tools to evaluate end stage (metastatic) disease. This poster details the development and characterization of orthotopic human ovarian cancer models using BLI.

Read this Poster to Discover:

• The development and characterization of SK-OV-3 and A2780 orthotopic, bioluminescent xenograft models, with successful abdominal tumor seeding confirmed by in-life imaging and ex vivo imaging at termination
• That paclitaxel treatment of the SK-OV-3-lux model from Day 11 significantly reduces tumor burden, as assessed by BLI
• That these bioluminescent ovarian cancer xenograft models provide essential insights into complex biological systems in animal models

Download the Poster Now!